Gossamer Bio Inc
For the period ended Jun 30, 2024. Filed Aug 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 12, 2024
GOSS$11.28+6.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six months ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities | ||
| Net income (loss) | $7,304 | $(91,661) |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Depreciation and amortization expense | 509 | 928 |
| Stock-based compensation expense | 10,812 | 16,324 |
| In process research and development expenses | — | 30 |
| Amortization of operating lease right-of-use assets | 1,469 | 1,363 |
| Amortization of long-term debt discount and issuance costs | 614 | 690 |
| Amortization of premium on marketable securities, net of accretion of discounts | (6,040) | (3,036) |
| Loss on disposal of property and equipment | 316 | — |
| Changes in operating assets and liabilities: | ||
| Receivable from contracts with collaborators | (3,629) | — |
| Prepaid expenses and other current assets | (2,692) | (5,048) |
| Other assets | 559 | (90) |
| Operating lease liabilities | (1,620) | (1,463) |
| Accounts payable | (4,441) | 716 |
| Accrued expenses and other current liabilities | (6,282) | (1,051) |
| Accrued research and development expenses | 3,082 | (3,564) |
| Accrued compensation and benefits | (2,476) | (5,335) |
| Contract liabilities | 66,696 | — |
| Accrued interest expense | (135) | (43) |
| Net cash provided by (used in) operating activities | 64,046 | (91,240) |
| Cash flows from investing activities | ||
| Research and development asset acquisitions, net of cash acquired | — | (30) |
| Purchase of marketable securities | (279,739) | (133,312) |
| Maturities of marketable securities | 282,300 | 155,000 |
| Net cash provided by investing activities | 2,561 | 21,658 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock pursuant to Employee Stock Purchase Plan | 348 | 367 |
| Proceeds from grant of equity option pursuant to Chiesi Collaboration Agreement | 464 | — |
| Principal repayments of long-term debt | (12,581) | (5,807) |
| Net cash used in financing activities | (11,769) | (5,440) |
| Effect of exchange rate changes on cash and cash equivalents | (70) | 53 |
| Net increase (decrease) in cash and cash equivalents | 54,768 | (74,969) |
| Cash and cash equivalents, at the beginning of the period | 32,109 | 111,973 |
| Cash, cash equivalents and restricted cash, at the end of the period | $86,877 | $37,004 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $5,561 | $6,283 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Change in unrealized gain (loss) on marketable securities, net | $(184) | $69 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.